Scarica l'app Stockscreener
4.01
1.72%
-0.07
Dopo l'orario di chiusura:
4.02
0.010
+0.25%
Precedente Chiudi:
$4.08
Aprire:
$3.96
Volume 24 ore:
76,016
Relative Volume:
0.39
Capitalizzazione di mercato:
$94.06M
Reddito:
$7.95M
Utile/perdita netta:
$-21.23M
Rapporto P/E:
-3.3403
EPS:
-1.2005
Flusso di cassa netto:
$-11.90M
1 W Prestazione:
-4.07%
1M Prestazione:
-18.33%
6M Prestazione:
-31.69%
1 anno Prestazione:
-38.69%
Intervallo 1D:
$3.91
$4.12
Intervallo di 1 settimana:
$3.7101
$4.19
Portata 52W:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
Nome
Coya Therapeutics Inc
Settore
Industria
Telefono
650.739.3939
Indirizzo
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.01 | 94.06M | 7.95M | -21.23M | -11.90M | -1.2005 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Lake Street | Buy |
| 2024-12-04 | Iniziato | D. Boral Capital | Buy |
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
Coya Therapeutics founder steps down, adds new director By Investing.com - au.investing.com
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent - PharmiWeb.com
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - BioSpace
Coya Therapeutics Announces Leadership Changes and New Director - TipRanks
COYA: Treg-focused therapies show promise in neurodegeneration, with pivotal trials underway - TradingView
Investor Presentation (04/02/2026 00: 00 - MarketScreener
Founder steps down as Coya Therapeutics (COYA) adds independent director Mark Pavao - Stock Titan
Coya Therapeutics founder steps down, adds new director - Investing.com
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Portfolio Update: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Market Mood & Reliable Intraday Trade Plans - baoquankhu1.vn
Death Cross: How do insiders feel about Coya Therapeutics IncExit Point & Daily Profit Focused Screening - baoquankhu1.vn
Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) PT at $16.00 - Defense World
Aug Sentiment: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Retail Activity & Technical Buy Zone Confirmation - baoquankhu1.vn
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - MSN
BTIG Reiterates Coya Therapeutics (COYA) Buy Recommendation - MSN
HC Wainwright Analysts Decrease Earnings Estimates for COYA - marketbeat.com
What is HC Wainwright’s Estimate for COYA Q1 Earnings? - Defense World
Sell Signal: How much upside does Coya Therapeutics Inc have2026 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at HC Wainwright - Defense World
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President a - pharmiweb.com
What is HC Wainwright's Estimate for COYA Q1 Earnings? - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating - TipRanks
Coya Therapeutics (COYA) Analyst Rating Reiterated at 'Buy' by H - GuruFocus
[EFFECT] Coya Therapeutics, In... | COYA SEC FilingForm EFFECT - Stock Titan
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
CEO Moves: Can Coya Therapeutics Inc sustain earnings growthInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
2.52M-share resale registration by Coya Therapeutics (NASDAQ: COYA) after Jan 2026 placement - stocktitan.net
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Business Wire
COYA SEC FilingsCoya Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Coya Therapeutics (COYA) Deepening Losses Challenge Bullish Growth Narrative After FY 2025 Results - simplywall.st
Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD - TipRanks
CGTX PE Ratio & Valuation, Is CGTX Overvalued - Intellectia AI
Treasury Yields: Is Coya Therapeutics Inc impacted by rising ratesBull Run & High Yield Equity Trading Tips - baoquankhu1.vn
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Reports 2025 Financial Results and Advances ALS & FTD Clinical Trials with Strong Cash Position - minichart.com.sg
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
COYA: Chardan Capital Maintains 'Buy' Rating with $14 Price Targ - GuruFocus
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics: Advancing Treg-Based Therapies for Neurodegenerative and Autoimmune Diseases - Minichart
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - BioSpace
Coya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Coya Therapeutics Incfiles for resale of up to 2.5 million shares of common stock by selling stockholdersSEC filing - marketscreener.com
Coya Therapeutics (NASDAQ: COYA) registers 2.52M private‑placement shares for resale - Stock Titan
Coya Therapeutics provides a corporate update and reports fiscal 2025 financial results - marketscreener.com
Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results - MarketBeat
Coya Therapeutics 2025 10-K: $7.95M Revenue; $(21.23)M Net Loss - TradingView
Coya Therapeutics Inc Azioni (COYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):